

Andrew E Hendifar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3391502/publications.pdf>

Version: 2024-02-01

99
papers

6,615
citations

136950

32
h-index

69250

77
g-index

100
all docs

100
docs citations

100
times ranked

9790
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase 3 Trial of ¹⁷⁷ Lu-Dotatate for Midgut Neuroendocrine Tumors. <i>New England Journal of Medicine</i> , 2017, 376, 125-135.	27.0	2,206
2	A Meta-Analysis of Osteosarcoma Outcomes in the Modern Medical Era. <i>Sarcoma</i> , 2012, 2012, 1-10.	1.3	323
3	Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial. <i>Lancet Oncology</i> , The, 2020, 21, 508-518.	10.7	323
4	Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3185-3194.	1.6	233
5	Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. <i>Cancer Discovery</i> , 2015, 5, 1040-1048.	9.4	226
6	Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers. <i>Gastroenterology</i> , 2019, 156, 2242-2253.e4.	1.3	224
7	¹⁷⁷ Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1752-1763.	10.7	195
8	Gender Disparities in Metastatic Colorectal Cancer Survival. <i>Clinical Cancer Research</i> , 2009, 15, 6391-6397.	7.0	168
9	Neuroendocrine Tumors of the Lung: Current Challenges and Advances in the Diagnosis and Management of Well-Differentiated Disease. <i>Journal of Thoracic Oncology</i> , 2017, 12, 425-436.	1.1	161
10	Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative. <i>Clinical Cancer Research</i> , 2018, 24, 5018-5027.	7.0	158
11	Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy. <i>JAMA Oncology</i> , 2017, 3, 516.	7.1	142
12	Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination. , 2018, 6, 46.		135
13	Phase II Study of the Safety and Antitumor Activity of the Hypoxia-Activated Prodrug TH-302 in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 3299-3306.	1.6	132
14	Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious <i>BRCA</i> Mutation. <i>JCO Precision Oncology</i> , 2018, 2018, 1-15.	3.0	129
15	Wearable activity monitors in oncology trials: Current use of an emerging technology. <i>Contemporary Clinical Trials</i> , 2018, 64, 13-21.	1.8	115
16	Wearable activity monitors to assess performance status and predict clinical outcomes in advanced cancer patients. <i>Npj Digital Medicine</i> , 2018, 1, 27.	10.9	111
17	A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer. <i>EBioMedicine</i> , 2019, 40, 375-381.	6.1	85
18	The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies. <i>Clinical and Translational Medicine</i> , 2019, 8, 9.	4.0	80

#	ARTICLE	IF	CITATIONS
19	Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2372-2382.	6.4	79
20	Identification of Targetable <i>ALK</i> Rearrangements in Pancreatic Ductal Adenocarcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 555-562.	4.9	79
21	Identifying prognostic intratumor heterogeneity using pre- and post-radiotherapy 18F-FDG PET images for pancreatic cancer patients. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 127-138.	1.4	62
22	Multifocality in Small Bowel Neuroendocrine Tumors. <i>Journal of Gastrointestinal Surgery</i> , 2018, 22, 303-309.	1.7	59
23	Cachexia, and not obesity, prior to pancreatic cancer diagnosis worsens survival and is negated by chemotherapy. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 17-23.	1.4	58
24	A virtual molecular tumor board to improve efficiency and scalability of delivering precision oncology to physicians and their patients. <i>JAMIA Open</i> , 2019, 2, 505-515.	2.0	56
25	A pilot study evaluating concordance between blood-based and patient-matched tumor molecular testing within pancreatic cancer patients participating in the Know Your Tumor (KYT) initiative. <i>Oncotarget</i> , 2017, 8, 83446-83456.	1.8	54
26	Review of systemic therapies for locally advanced and metastatic rectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, 185-200.	1.4	45
27	Influence of Body Mass Index and Albumin on Perioperative Morbidity and Clinical Outcomes in Resected Pancreatic Adenocarcinoma. <i>PLoS ONE</i> , 2016, 11, e0152172.	2.5	43
28	Comparing Physician and Nurse Eastern Cooperative Oncology Group Performance Status (ECOG-PS) Ratings as Predictors of Clinical Outcomes in Patients with Cancer. <i>Oncologist</i> , 2019, 24, e1460-e1466.	3.7	42
29	The use of Ki-67 labeling index to grade pulmonary well-differentiated neuroendocrine neoplasms: current best evidence. <i>Modern Pathology</i> , 2018, 31, 1523-1531.	5.5	41
30	Statins and pancreatic cancer. <i>Oncology Letters</i> , 2017, 13, 1035-1040.	1.8	40
31	Outcomes in Patients With Pancreatic Adenocarcinoma With Genetic Mutations in DNA Damage Response Pathways: Results From the Know Your Tumor Program. <i>JCO Precision Oncology</i> , 2019, 3, 1-10.	3.0	38
32	Aldoxorubicin: a tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 777-786.	4.3	37
33	Cultured circulating tumor cells and their derived xenografts for personalized oncology. <i>Asian Journal of Urology</i> , 2016, 3, 240-253.	1.2	33
34	Meta-analyses of treatment standards for pancreatic cancer. <i>Molecular and Clinical Oncology</i> , 2016, 4, 315-325.	1.0	31
35	Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade. <i>Clinical and Translational Medicine</i> , 2018, 7, 32.	4.0	29
36	Advances in Pancreatic Ductal Adenocarcinoma Treatment. <i>Cancers</i> , 2021, 13, 5510.	3.7	28

#	ARTICLE	IF	CITATIONS
37	A phase I/II study of rovalpituzumab tesirine in delta-like 3 ⁺ expressing advanced solid tumors. <i>Npj Precision Oncology</i> , 2021, 5, 74.	5.4	27
38	Most of the Intended Management Changes After 68Ga-DOTATATE PET/CT Are Implemented. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1793-1796.	5.0	24
39	An open-label, single-arm pilot study of EUS-guided brachytherapy with phosphorus-32 microparticles in combination with gemcitabine +/- nab-paclitaxel in unresectable locally advanced pancreatic cancer (OncoPaC-1): Technical details and study protocol. <i>Endoscopic Ultrasound</i> , 2020, 9, 24.	1.5	23
40	Therapeutic targeting of SLC6A8 creatine transporter suppresses colon cancer progression and modulates human creatine levels. <i>Science Advances</i> , 2021, 7, eabi7511.	10.3	23
41	The role of preoperative imaging and double balloon enteroscopy in the surgical management of small bowel neuroendocrine tumors: Is it necessary?. <i>Journal of Surgical Oncology</i> , 2018, 117, 207-212.	1.7	22
42	Myositis ossificans: A case report. <i>Arthritis and Rheumatism</i> , 2005, 53, 793-795.	6.7	20
43	Do changes in health reveal the possibility of undiagnosed pancreatic cancer? Development of a risk-prediction model based on healthcare claims data. <i>PLoS ONE</i> , 2019, 14, e0218580.	2.5	19
44	Targeting the Fibroblast Growth Factor Receptor (FGFR) in Advanced Cholangiocarcinoma: Clinical Trial Progress and Future Considerations. <i>Cancers</i> , 2021, 13, 1706.	3.7	19
45	Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States. <i>Hepatology</i> , 2022, 76, 1649-1659.	7.3	18
46	Feasibility and efficacy of enteral tube feeding on weight stability, lean body mass, and patient-reported outcomes in pancreatic cancer cachexia. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 1959-1968.	7.3	17
47	Six-dimensional quantitative DCE MR Multitasking of the entire abdomen: Method and application to pancreatic ductal adenocarcinoma. <i>Magnetic Resonance in Medicine</i> , 2020, 84, 928-948.	3.0	16
48	Dosimetric evaluation of simultaneous integrated boost during stereotactic body radiation therapy for pancreatic cancer. <i>Medical Dosimetry</i> , 2015, 40, 47-52.	0.9	15
49	Long-Term Outcomes after Elective versus Emergency Surgery for Small Bowel Neuroendocrine Tumors. <i>American Surgeon</i> , 2018, 84, 1570-1574.	0.8	15
50	Multi-omic molecular comparison of primary versus metastatic pancreatic tumours. <i>British Journal of Cancer</i> , 2019, 121, 264-270.	6.4	15
51	Landscape of Health-Related Quality of Life in Patients With Early-Stage Pancreatic Cancer Receiving Adjuvant or Neoadjuvant Chemotherapy. <i>Pancreas</i> , 2020, 49, 393-407.	1.1	15
52	Remote Oncology Care: Review of Current Technology and Future Directions. <i>Cureus</i> , 2020, 12, e10156.	0.5	15
53	Identification of Actionable Fusions as an Anti-EGFR Resistance Mechanism Using a Circulating Tumor DNA Assay. <i>JCO Precision Oncology</i> , 2019, 3, 1-15.	3.0	14
54	Immunotherapy Updates in Advanced Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 2164.	3.7	14

#	ARTICLE	IF	CITATIONS
55	Retrospective Case Series Analysis of <i>RAF</i> Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies. <i>JCO Precision Oncology</i> , 2021, 5, 1325-1338.	3.0	14
56	Recent Advances in Targeted Therapies for Advanced Gastrointestinal Malignancies. <i>Cancers</i> , 2020, 12, 1168.	3.7	13
57	Midgut Neuroendocrine Tumors with Liver-only Metastases: Benefit of Primary Tumor Resection. <i>Annals of Surgical Oncology</i> , 2020, 27, 4525-4532.	1.5	13
58	Symptom Management in Pancreatic Cancer. <i>Current Treatment Options in Oncology</i> , 2021, 22, 8.	3.0	13
59	Moving Beyond Conventional Clinical Trial End Points in Treatment-refractory Metastatic Colorectal Cancer: A Composite Quality-of-life and Symptom Control End Point. <i>Clinical Therapeutics</i> , 2017, 39, 2135-2145.	2.5	12
60	Palliative Radiation Therapy for Bone Metastases in Neuroendocrine Neoplasms. <i>Advances in Radiation Oncology</i> , 2019, 4, 513-519.	1.2	12
61	Checkpoint inhibition in advanced gastroesophageal cancer: clinical trial data, molecular subtyping, predictive biomarkers, and the potential of combination therapies. <i>Translational Gastroenterology and Hepatology</i> , 2019, 4, 63-63.	3.0	12
62	Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with ¹⁷⁷ Lu-DOTATATE. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1712-1718.	5.0	12
63	Clinical Applications of Minimal Residual Disease Assessments by Tumor-Informed and Tumor-Uninformed Circulating Tumor DNA in Colorectal Cancer. <i>Cancers</i> , 2021, 13, 4547.	3.7	12
64	Current Practices and Novel Techniques in the Diagnosis and Management of Neuroendocrine Tumors of Unknown Primary. <i>Pancreas</i> , 2019, 48, 1111-1118.	1.1	11
65	Exploiting Temozolomide-Induced Hypermutation With Pembrolizumab in a Refractory High-Grade Neuroendocrine Neoplasm: A Proof-of-Concept Case. <i>JCO Precision Oncology</i> , 2020, 4, 614-619.	3.0	11
66	Prognostic Factors Associated with Outcomes in Small Bowel Neuroendocrine Tumors. <i>American Surgeon</i> , 2017, 83, 1174-1178.	0.8	10
67	Prognostic factors influencing survival in small bowel neuroendocrine tumor with liver metastases. <i>Journal of Surgical Oncology</i> , 2019, 120, 926-931.	1.7	10
68	Treatment strategies and clinical outcomes of locally advanced pancreatic cancer patients treated at high-volume facilities and academic centers. <i>Advances in Radiation Oncology</i> , 2019, 4, 302-313.	1.2	10
69	Impact of margin status and lymphadenectomy on clinical outcomes in resected pancreatic adenocarcinoma: implications for adjuvant radiotherapy. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 239-47.	1.4	8
70	A Comparison of Clinicopathologic Outcomes Across Neoadjuvant and Adjuvant Treatment Modalities in Resectable Gastric Cancer. <i>JAMA Network Open</i> , 2021, 4, e2138432.	5.9	8
71	ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series. <i>JCO Precision Oncology</i> , 2022, 6, e2200015.	3.0	8
72	¹⁸ F-FDG PET Predicts Hematologic Toxicity in Patients with Locally Advanced Anal Cancer Treated With Chemoradiation. <i>Advances in Radiation Oncology</i> , 2019, 4, 613-622.	1.2	7

#	ARTICLE	IF	CITATIONS
73	Stromal hyaluronan accumulation is associated with low tumor grade and nodal metastases in pancreatic ductal adenocarcinoma. <i>Human Pathology</i> , 2019, 90, 37-44.	2.0	7
74	Molecular Targets, Pathways, and Therapeutic Implications for Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5232.	4.1	7
75	Efficacy of PD-1 Blockade in Refractory Microsatellite-Stable Colorectal Cancer With High Tumor Mutation Burden. <i>Clinical Colorectal Cancer</i> , 2019, 18, 307-309.	2.3	6
76	Pancreatic cancer "mismatch"™ in Lynch syndrome. <i>BMJ Open Gastroenterology</i> , 2019, 6, e000274.	2.7	6
77	The Evolving Treatment Algorithm for Advanced Neuroendocrine Neoplasms: Diversity and Commonalities Across Tumor Types. <i>Oncologist</i> , 2019, 24, 54-61.	3.7	6
78	Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Treated With Liposomal Irinotecan. <i>Frontiers in Oncology</i> , 2021, 11, 678070.	2.8	6
79	Leveraging patient-reported outcomes (PROs) in patients with pancreatic cancer: The Pancreatic Cancer Action Network (PanCAN) online patient registry experience. <i>Cancer Medicine</i> , 2021, 10, 7152-7161.	2.8	6
80	Multiplatform profiling of pancreatic neuroendocrine tumors: Correlative analyses of clinicopathologic factors and identification of co-occurring pathogenic alterations. <i>Oncotarget</i> , 2019, 10, 6260-6268.	1.8	6
81	Hyaluronan heterogeneity in pancreatic ductal adenocarcinoma: Primary tumors compared to sites of metastasis. <i>Pancreatology</i> , 2022, 22, 92-97.	1.1	4
82	Lung Neuroendocrine Tumors: How Does Molecular Profiling Help?. <i>Current Oncology Reports</i> , 2022, 24, 819-824.	4.0	4
83	Circulating tumor DNA dynamics and response to immunotherapy in colorectal cancer. <i>Molecular and Clinical Oncology</i> , 2022, 16, 100.	1.0	4
84	Biomarker-driven EGFR therapy improves outcomes in patients with metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1051-1061.	2.4	3
85	Private Funding for Pancreatic Cancer Research: More Than a Chip Shot. <i>Gastroenterology</i> , 2017, 152, 918-921.e2.	1.3	3
86	Primary Visceral Merkel Cell Carcinoma: A Case Report and Review of the Literature. <i>American Journal of Dermatopathology</i> , 2018, 40, 927-929.	0.6	3
87	Impact of palliative therapies in metastatic esophageal cancer patients not receiving chemotherapy. <i>World Journal of Gastrointestinal Surgery</i> , 2020, 12, 377-389.	1.5	3
88	Raynaud's Phenomenon From PD-1 Immune Checkpoint Inhibition. <i>JCO Oncology Practice</i> , 2020, 16, 701-702.	2.9	2
89	Evaluation of Minimal Important Difference and Responder Definition in the EORTC QLQ-PAN26 Module for Assessing Health-Related Quality of Life in Patients with Surgically Resected Pancreatic Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 7545-7554.	1.5	2
90	Pretreatment [18F] FDG-PET texture analysis to predict local response of pancreatic cancer to radiotherapy.. <i>Journal of Clinical Oncology</i> , 2014, 32, 375-375.	1.6	2

#	ARTICLE	IF	CITATIONS
91	Best Practices for the Coordinated Care of Patients With Neuroendocrine Tumors Undergoing Peptide Receptor Radionuclide Therapy. <i>Pancreas</i> , 2022, 51, 213-218.	1.1	2
92	Combined morphologic and metabolic pipeline for Positron emission tomography/computed tomography based radiotherapy response evaluation in locally advanced pancreatic adenocarcinoma. <i>Physics and Imaging in Radiation Oncology</i> , 2019, 9, 28-34.	2.9	1
93	Fecal elastase, an assay for exocrine pancreatic insufficiency, has clinical utility in patients with pancreatic ductal adenocarcinoma. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482096431.	3.2	1
94	Dual Checkpoint Blockade in a Neuroendocrine Carcinoma With Dual PD-L1/PD-L2 Amplification and High Tumor Mutational Burden. <i>JCO Precision Oncology</i> , 2020, 4, 514-519.	3.0	1
95	A Rare Case of Primary Gastric HIV-Associated Peripheral T-Cell Lymphoma: Relapsed Disease Treated With Pemetrexed. <i>World Journal of Oncology</i> , 2013, 4, 217-220.	1.5	1
96	Chemotherapy predictors and a time-dependent chemotherapy effect in metastatic esophageal cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2022, 14, 511-524.	2.0	1
97	Therapeutic Advances and Challenges in the Management of HER2-Positive Gastroesophageal Cancers. <i>Diseases (Basel, Switzerland)</i> , 2022, 10, 23.	2.5	1
98	A radiopaque polymer hydrogel as an irreversible electroporation compatible fiducial marker for pancreas stereotactic body radiotherapy. <i>Journal of Radiosurgery and SBRT</i> , 2020, 7, 165-167.	0.2	0
99	318â€¦Olaparib plus pembrolizumab in patients with previously treated advanced solid tumors with homologous recombination repair mutation and/or homologous recombination repair deficiency: KEYLYNK-007. , 2020, , .		0